Abstract: |
Following treatment for urothelial carcinoma of the bladder (UCB), patients are at risk for urothelial recurrence in the bladder, urethra and upper tracts. This may be due to a field effect in the urothelium or implantation of malignant cells shed from the primary tumor [1]. Conversely, following treatment for upper tract urothelial carcinomas (UTUC) there is a 13-54 % and 6 % risk of recurrence in the bladder and contralateral upper tract, respectively [2]. Theoretical causes for intravesical recurrence following treatment for UTUC include tumor cell shedding during surgery, angiogenic factors released into the bladder as a consequence of the bladder incision, and a compromised immune status due to surgery [3]. Because there is a risk of UTUC after treatment for UCB, and UCB after treatment for UTUC, long-term surveillance of the urothelium is necessary in patients with a history of urothelial carcinoma. © Springer International Publishing Switzerland 2015. |